Tempest Therapeutics, Inc. has announced its financial results for the third quarter of 2026, marking a significant period of advancement for the clinical-stage biotechnology company. The results were disclosed in a recent filing, emphasizing the company's progress in developing innovative CAR-T therapies aimed at treating cancer and autoimmune diseases.

On November 13, 2026, Tempest released a press statement detailing its financial performance for the quarter ended September 30, 2026. The company reported meaningful strides in its pipeline, particularly with its lead candidate, TPST-4903, which targets BCMA/GPRC5D through a newly licensed in vivo CAR-T platform from Senlang.

Tempest's CEO, Matt Angel, highlighted the strategic collaboration with Senlang as a pivotal move that strengthens the company's position in the evolving CAR-T landscape. He stated, "The third quarter marked a period of meaningful progress in the advancement of two next-generation in vivo CAR-T platforms with the potential to transform treatment across multiple diseases." This collaboration is expected to enhance Tempest's capabilities in developing effective therapies.

Additionally, the company secured access to significant funding, including an equity line of credit with Lincoln Park Capital Fund of up to $50 million and a private placement that generated approximately $2.5 million in gross proceeds. This financial backing will support Tempest's ongoing development priorities and expansion efforts.

Tempest also announced the strengthening of its Board of Directors with the appointments of Nancy Freda-Smith and John W. Frederick, both bringing valuable expertise in corporate governance and capital markets. These appointments are seen as a strategic move to navigate the next phase of the company's growth.

Founded in 2012 and based in Brisbane, California, Tempest Therapeutics operates under the SIC classification of Pharmaceutical Preparations (SIC 2834). The company trades on the Nasdaq under the ticker TPST.

The SEC filing also noted that the information provided, including the attached press release, is being furnished under Item 2.02, which pertains to results of operations and financial condition. However, it is important to note that this information is not deemed "filed" under the Securities Exchange Act of 1934, nor is it subject to the liabilities of that section.

As for the immediate future, the filing does not specify what actions Tempest Therapeutics will take next beyond the announcements made. However, the recent developments suggest a proactive approach as the company seeks to capitalize on its advancements and funding opportunities.